# 2026-09012: FDA Yanks 15 Teva Generic Approvals for Dormant Drugs

2026-09012, Teva Pharmaceuticals USA, Inc., et al.; Withdrawal of Approval of 15 Abbreviated New Drug Applications, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-05-07, effective 2026-06-08; PRIA reads it as touching household money (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-09012
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-09012
- Title: Teva Pharmaceuticals USA, Inc., et al.; Withdrawal of Approval of 15 Abbreviated New Drug Applications
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 24879
- Published: 2026-05-07
- Effective: 2026-06-08
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Yanks 15 Teva Generic Approvals for Dormant Drugs

## Summary

The FDA is officially pulling the plug on 15 generic drug approvals from Teva Pharmaceuticals and its related companies because these drugs aren’t being sold anymore. This change kicks in on June 8, 2026, and it won’t cost anyone money or cause shortages since the drugs are off the market. If Teva wants, they can ask to sell these drugs again later without any trouble.

## Abstract

The Food and Drug Administration (FDA or Agency) is withdrawing approval of 15 abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

## Effects PRIA read

- FDA withdraws 15 generic approvals: cost, medium. The FDA is withdrawing approval of 15 abbreviated new drug applications (ANDAs) from multiple applicants, including Teva Pharmaceuticals USA and related companies, effective June 8, 2026. The listed applicants requested withdrawal and waived their opportunity for a hearing. The withdrawal is withou…
- Existing stock can still be dispensed: benefit, low. If any of the listed drug products are in inventory on June 8, 2026, they may continue to be dispensed until inventories are depleted, the products reach their expiration dates, or they otherwise become violative. After those conditions occur, the products may not be introduced into interstate comm…
- FDA says no cost or shortage expected: benefit, low. The FDA states the withdrawals apply to drug products that are no longer marketed and that the change takes effect on June 8, 2026. Because these products are off the market, the action is described as not causing costs to consumers or drug shortages.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-09012 on federalregister.gov](https://www.federalregister.gov/documents/2026/05/07/2026-09012/teva-pharmaceuticals-usa-inc-et-al-withdrawal-of-approval-of-15-abbreviated-new-drug-applications)
- [2026-09012 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-05-07/pdf/2026-09012.pdf)

## Related
- [Previous: 2026-09011, Determination That MICARDIS (Telmisartan), Tablets, 20 Milligrams and 80 Millig…](https://policyrisk.com/federal-register/2026-09011)
- [Next: 2026-09013, Final Flood Hazard Determinations](https://policyrisk.com/federal-register/2026-09013)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-09012 (as of 2026-06-08).
